Active Substance: human alpha1-proteinase inhibitor
Common Name: human alpha1-proteinase inhibitor
ATC Code: B02AB02
Marketing Authorisation Holder: CSL Behring GmbH
Active Substance: human alpha1-proteinase inhibitor
Authorisation Date: 2015-08-20
Therapeutic Area: Genetic Diseases, Inborn Lung Diseases
Pharmacotherapeutic Group: Antihemorrhagics
Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.
What is Respreeza and what is it used for?
Respreeza is a medicine used in adults with alpha1-proteinase inhibitor deficiency, an inherited disorder that can cause lung problems such as increasing shortness of breath and which may also affect the liver. Respreeza is used to slow down damage to the lungs in patients with severe disease.
Respreeza contains the active substance human alpha1-proteinase inhibitor.
How is Respreeza used?
Respreeza is available as a powder and solvent to be made into a solution for infusion (drip) into a vein. The first infusion should be given under the supervision of a healthcare professionals experienced in the treatment of alpha1-proteinase inhibitor deficiency. Subsequent infusions can be given by a caregiver or by the patient.
The recommended dose of Respreeza is 60 mg per kilogram body weight, given once a week. The infusion should last around 15 minutes.
The medicine can only be obtained with a prescription. For further information, see the package leaflet.
How does Respreeza work?
The active substance in Respreeza, human alpha1-proteinase inhibitor, is a natural component of the blood whose function is to protect the lung tissue from damage. It is obtained from human blood and works by replacing the protein that is lacking in patients with alpha1-proteinase inhibitor deficiency.
What benefits of Respreeza have been shown in studies?
Respreeza has been shown to slow down lung damage in one main study involving 180 patients with lung damage due to alpha1-proteinase inhibitor deficiency. In the study, Respreeza was compared with placebo (a dummy treatment) and the main measure of effectiveness was the decrease in lung density. Lung density is an indicator of the extent of lung damage: the bigger the decrease in lung density, the greater is the damage to the lung. The decrease in lung density after 24 months was around 2.6 g/l in patients who received Respreeza, compared with a decrease of around 4.2 g/l in patients receiving placebo.
What are the risks associated with Respreeza?
The most common side effects with Respreeza (which may affect up to 1 in 10 people) are dizziness and headache. Allergic reactions have been observed during treatment, some of which were severe.
Because of the risk of severe allergic reactions, Respreeza must not be used in patients who are lacking a protein in the blood called IgA and who have developed antibodies against it, as these patients are more prone to allergic reactions. For the full list of all side effects and restrictions with Respreeza, see the package leaflet.
Why is Respreeza approved?
The main study with Respreeza showed that the medicine is effective at slowing down the damage to the lungs in patients with alpha1-proteinase inhibitor deficiency, and this effect is considered relevant for patients with severe disease. Allergic reactions were the main safety concern with Respreeza, but advice on how to manage this risk has been included in the product information. No other major concerns have been identified about the safety of the medicine.
Therefore, the Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Respreeza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
What measures are being taken to ensure the safe and effective use of Respreeza?
A risk management plan has been developed to ensure that Respreeza is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Respreeza, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, the company that markets Respreeza will carry out a further study to assess whether an increased dose of 120 mg/kg may lead to improved effects compared with the currently recommended dose.
Further information can be found in the summary of the risk management plan.
Other information about Respreeza
The European Commission granted a marketing authorisation valid throughout the European Union for Respreeza on 20 August 2015.
For more information about treatment with Respreeza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.